Akèy › Limfom Difize Gwo Selil B › Oregon › Portland
Etid klinik pou Limfom Difize Gwo Selil B nan Portland, OR
15 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan ak bò kote Portland (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Ap rekriteFaz 2
- Oregon Health and Science University, Portland
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Ap rekriteFaz 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Ap rekriteFaz 3
- Kaiser Permanente Interstate Medical Office - Central ( Site 0181), Portland
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Ap rekriteFaz 2
- Providence Portland Medical Center ( Site 0120), Portland
- Providence Oncology and Hematology Clinic Westside ( Site 0179), Portland
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Ap rekriteEtid obsèvasyon
- OHSU Knight Cancer Institute, Portland
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Ap rekriteFaz 1
- Oregon Health & Science University (OHSU), Portland
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Ap rekriteFaz 1/2
- Oregon Health and Science University ( Site 1004), Portland
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Ap rekriteFaz 2
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
- Oregon Health & Science University, Portland
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Ap rekriteEtid obsèvasyon
- Oregon Health and Science University Knight Cancer Institute, Portland
DALY II USA/ MB-CART2019.1 for DLBCL
Ap rekriteFaz 2
- Oregon Health and Science University Knight Cancer Institute, Portland
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
Ap rekriteFaz 1/2
- OHSU Knight Cancer Institute, Portland
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Ap rekriteFaz 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- ak 1 plis
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Ap rekriteFaz 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mi lwen
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Ap rekriteFaz 1
- Oregon Health & Science University, Portland
Etid Limfom Difize Gwo Selil B nan lòt vil
- New York City, NY21 etid
- Baldwin Park, CA19 etid
- Chicago, IL18 etid
- Houston, TX17 etid
- Los Angeles, CA17 etid
- Boston, MA16 etid
- Milwaukee, WI16 etid
- Nashville, TN15 etid
- Philadelphia, PA15 etid
- Durham, NC14 etid
- Dallas, TX13 etid
- Seattle, WA12 etid
Lòt etid nan Portland
- Kansè Poumon ki pa ti selil46 etid
- Kansè (tout kalite)34 etid
- Kansè pwostat33 etid
- Kansè nan tete33 etid
- Kansè Metastatik29 etid
- Kansè kolorektal28 etid
- Kansè ovè27 etid
- Kansè poumon26 etid
- Leksemi mieloïd egi25 etid
- Kansè Endomèt24 etid
- Karsinòm selil skuamèz tèt ak kou19 etid
- Kansè pankreyas19 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.